
Sign up to save your podcasts
Or


Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022.
Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major research trend that flew under the radar this year: increased public and private funding for trials looking into therapeutic psychedelics.
By Axios4.3
689689 ratings
Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022.
Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major research trend that flew under the radar this year: increased public and private funding for trials looking into therapeutic psychedelics.

32,045 Listeners

8,770 Listeners

4,182 Listeners

3,972 Listeners

1,519 Listeners

700 Listeners

112,881 Listeners

2,326 Listeners

7,203 Listeners

2,022 Listeners

5,488 Listeners

4,366 Listeners

16,095 Listeners

10,873 Listeners

8,744 Listeners

1,604 Listeners

567 Listeners